### **Infectious and Neglected diseases**

## Poster

# Structural perspective into rabies virus neutralization

### Ashwini Kedari<sup>1</sup> and Ilona Rissanen<sup>1</sup>

<sup>1</sup>Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

#### ashwini.kedari@helsinki.fi

Rabies virus (RABV) is a lethal neurotropic virus which causes approximately 60,000 deaths annually [1, 2]. The trimeric glycoprotein (G) spikes of RABV are the only surface-exposed proteins on the virion and mediates receptor recognition and host cell entry [3, 4]. RABV-G displays several epitopes which are targeted by antibodies, including neutralizing monoclonal antibodies (mAb) that have been proposed as effective alternatives to traditional polyclonal rabies immunoglobulin treatment [5-7]. In this study, one such neutralizing antibody, CR57, was engineered into a diabody to enable crystallization in complex with the targeted domain from rabies G. Here, we report the crystal structure of the RABV-G domain III in complex with the CR57 diabody at 2.7 Å resolution. The structure reveals the antibody epitope, where key interactions are targeted at a 6-residue hydrophobic peptide on RABV-G. We present an antigenic mapping of all known epitopes on the spike, which reveals two predominant sites of vulnerability to neutralization. Based on a structural analysis, we postulate two possible mechanisms for CR57-mediated neutralization: steric occlusion of receptor binding and of the fusogenic conformational changes. Our results provide a molecular description for rabies inhibition by one of the most potent antibodies against diverse rabies strains. This study also showcases the importance of the diabody as a crystallization scaffold for challenging targets.

Figure 1. A) Schematic representation of the design of CR57 diabody. Antigen (Ag) binding sites are denoted. B) Crystal structure of the CR57 diabody



B) Crystal structure of the CR57 diabody in complex with RABV-G domain III, Resolution 2.70Å



in complex with RABV-G domain III, resolved at 2.7Å resolution, and a magnified view of the CR57 diabody– RABV-G domain III interface, where key interacting residues are labelled and shown as sticks with oxygen atoms in red and nitrogen atoms in blue.

- 1. Hampson, K., et al., Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis, 2015. 9(4): p. e0003709.
- 2. Thumbi, S.M., et al., A call to accelerate an end to human rabies deaths. Lancet, 2022. 400(10369): p. 2261-2264.
- 3. Fooks, A.R., et al., Rabies. Nat Rev Dis Primers, 2017. 3: p. 17091.
- 4. Schnell, M.J., et al., The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol, 2010. 8(1): p. 51-61.
- 5. Callaway, H.M., et al., *Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody*. Sci Adv, 2022. 8(24): p. eabp9151.
- 6. Hellert, J., et al., Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. Nat Commun, 2020. 11(1): p. 596.
- 7. Ng, W.M., et al., *Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies*. Cell Host Microbe, 2022. 30(9): p. 1219-1230 e7.